| Literature DB >> 35875276 |
Fatemeh Javaherforooshzadeh1, Mohammadreza Amjadzadeh2, Habib Haybar3, Amir Sharafkhaneh4.
Abstract
Purpose Obstructive sleep apnea (OSA) is a common and often undiagnosed condition in patients undergoing major surgeries, including cardiac surgery. This disorder is associated with peri- and postoperative problems. This study measured the association between OSA and peri- and postoperative complications in patients undergoing elective cardiac surgery. Methods Candidates for elective cardiac surgery were evaluated for OSA by the STOP-Bang questionnaire before the surgery. We evaluated patients before and after the operation regarding the cardiac, respiratory, and neurologic complications. We divided the participants into high-risk (score of 5-8), intermediate-risk (score of 3-4), and low-risk groups (score of 0-2) based on the STOP-Bang questionnaire. Results Of the 306 patients who underwent cardiac surgery, 173 (56.5%) were in the high-risk group, 100 (32.7%) were in the intermediate-risk group, and 33 (10.8%) were in the low-risk group for OSA. Patients in the high-risk group were significantly older than the other two groups (p value=0.013), had higher BMI (p<0.001), and suffered more from relevant comorbid conditions, including diabetes mellitus, hypertension, and hyperlipidemia (all p-values significant at < 0.05). However, not significant, patients in the high-risk group suffered more from postoperative complications including cardiac, respiratory, and neurological complications. Conclusion OSA is common in patients undergoing cardiac surgery. Our findings indicate that these patients manifest a higher incidence of postoperative complications compared to those with a lower risk of OSA. Because of the limited use of polysomnography, a simple STOP-Bang questionnaire is beneficial to screen patients for the risk of OSA peri-operatively, and patients diagnosed with OSA can get extra care during and after the surgery.Entities:
Keywords: cardiac surgery; coronary artery disease; obstructive sleep apnea; sleep disordered breathing; stop-bang questionnaire
Year: 2022 PMID: 35875276 PMCID: PMC9297118 DOI: 10.7759/cureus.26102
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Baseline Characteristics of the Study Population
BMI, body mass index (kg/m2); HTN, hypertension; MI, myocardial infarction; HF, heart failure; TIA/CVA, transient ischemic attack/cerebrovascular accident; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GFR, glomerular filtration rate (mL/min/1.73 m2)
*Statistically significant.
| Characteristics | Low Risk, 33 (10.8%) | Intermediate Risk, 100 (32.7%) | High Risk, 173 (56.5%) | p-Value |
| Demographics | ||||
| Age | 54.5±12.9 | 59.1±10.2 | 60.1±8.6 | 0.013* |
| Sex (male) | 8 (24.2) | 62 (62) | 129 (74.6) | <0.001* |
| BMI | 27.1±3.6 | 27.1±4.2 | 29.5±4.8 | <0.001* |
| Baseline characteristics | ||||
| HTN | 20 (60.6) | 76 (76) | 163 (94.2) | <0.001* |
| Pulmonary HTN | 0 (0.0) | 2 (2) | 0 (0.0) | - |
| Previous MI | 9 (27.3) | 38 (38) | 70 (40.5) | 0.360 |
| HF | 12 (36.4) | 49 (49) | 76 (43.9) | 0.424 |
| TIA/CVA | 4 (12.1) | 9 (9) | 16 (9.2) | 0.858 |
| COPD | 1 (3.0) | 16 (16) | 27 (15.6) | 0.130 |
| DM | 14 (42.4) | 46 (46) | 103 (59.5) | 0.041* |
| Hyperlipidemia | 18 (54.5) | 60 (60) | 140 (80.9) | <0.001* |
| Hypothyroidism | 0 (0.0) | 2 (2) | 2 (1.2) | 0.763 |
| Smoking | 5 (15.2) | 37 (37) | 75 (43.4) | 0.009* |
| Creatinine (mg/dL) | 1.0±0.2 | 1.2±0.8 | 1.2±0.3 | 0.306 |
| GFR | 72.5±21.6 | 74.5±29.5 | 78.5±26.0 | 0.330 |
| Drug history | ||||
| Beta-blockers | 19 (57.6) | 67 (67.0) | 111 (64.2) | 0.616 |
| Calcium channel blockers | 2 (6.1) | 15 (15.0) | 43 (24.9) | 0.016* |
| Angiotensin II receptor blockers | 10 (30.3) | 37 (37.0) | 93 (53.8) | 0.005* |
| Angiotensin-converting enzyme inhibitors | 4 (12.1) | 16 (16.0) | 27 (15.6) | 0.858 |
| Diuretics | 11 (33.3) | 31 (31.0) | 67 (38.7) | 0.420 |
| Statins | 14 (42.4) | 71 (71.0) | 146 (84.4) | <0.001* |
| Aspirin | 20 (60.6) | 81 (81.0) | 145 (83.8) | 0.009* |
| Clopidogrel | 16 (48.5) | 51 (51.0) | 90 (52.0) | 0.930 |
| Nitrocontin | 8 (24.2) | 42 (42.0) | 86 (49.7) | 0.022* |
Angiographic and Echocardiographic Characteristics of the Study Population
LVEF, left ventricular ejection fraction (%)
*Statistically significant.
| Characteristics | Low Risk, 33 (10.8%) | Intermediate Risk, 100 (32.7%) | High Risk, 173 (56.5%) | p-Value |
| One-vessel disease | 0 (0.0) | 10 (10.0) | 0 (0.0) | <0.001* |
| Two-vessel disease | 4 (12.1) | 10 (10.0) | 18 (10.4) | 0.942 |
| Three-vessel disease | 20 (60.6) | 72 (72.0) | 151 (87.3) | <0.001* |
| LVEF | 43.9±9.6 | 42.7±10.9 | 42.5±11.4 | 0.808 |
| Aortic valve stenosis | 0 (0.0) | 4 (4.0) | 8 (4.6) | 0.455 |
| Aortic valve insufficiency | 12 (34.6) | 31 (31.0) | 62 (35.8) | 0.695 |
| Pulmonary valve insufficiency | 13 (39.4) | 42 (42.0) | 77 (44.5) | 0.829 |
| Mitral valve Insufficiency | 0 (0.0) | 2 (2.0) | 0 (0.0) | 0.188 |
| Mitral valve stenosis | 5 (15.2) | 2 (2.0) | 2 (1.2) | 0.001 |
| Mitral valve regurgitation | 27 (81.8) | 83 (83.0) | 135 (78.0) | 0.592 |
| Tricuspid valve regurgitation | 24 (72.7) | 69 (69.0) | 126 (72.8) | 0.786 |
Intraoperative Data of the Study Population
CABG, coronary artery bypass grafting; ASD, atrial septal defect; VSD, ventricular septal defect; HTN, hypertension
*Statistically significant.
| Characteristics | Low Risk, 33 (10.8%) | Intermediate Risk, 100 (32.7%) | High Risk, 173 (56.5%) | p-Value |
| Type of operation | ||||
| CABG only | 22 (66.6) | 90 (90.0) | 157 (90.8) | <0.001* |
| Valve repair only | 0 (0.0) | 0 (0.0) | 2 (1.2) | 0.461 |
| Valve replacement only | 7 (21.2) | 4 (4.0) | 2 (1.2) | <0.001* |
| ASD repair only | 2 (6.1) | 2 (2.0) | 0 (0.0) | 0.015* |
| VSD repair only | 0 (0.0) | 2 (2.0) | 0 (0.0) | 0.126 |
| CABG/valve replacement/ ASD repair | 2 (6.1) | 0 (0.0) | 0 (0.0) | <0.001* |
| CABG/valve repair | 0 (0.0) | 1 (1.0) | 4 (2.3) | 0.806 |
| CABG/valve replacement | 0 (0.0) | 1 (1.0) | 6 (3.5) | 0.435 |
| Valve repair/ASD repair | 0 (0.0) | 0 (0.0) | 1 (0.6) | >0.999 |
| Valve repair/valve replacement | 0 (0.0) | 0 (0.0) | 1 (0.6) | >0.999 |
| Intraoperative outcomes | ||||
| Difficult intubation | 0 (0.0) | 9 (9.0) | 8 (4.6) | 0.109 |
| Hypoxemia | 1.1±0.2 | 1.0±0.2 | 1.1±0.3 | 0.246 |
| Arrhythmia | 0(0.0) | 2(2.0) | 4 (2.3) | >0.999 |
| HTN | 7 (21.2) | 30 (30.0) | 56 (32.4) | 0.440 |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
Postoperative Outcomes of the Study Population
AF, atrial fibrillation; HTN, hypertension; MI, myocardial infarction; ICU, intensive care unit; LoS, length of stay
*Statistically significant.
| Characteristics | Low Risk, 33 (10.8%) | Intermediate Risk, 100 (32.7%) | High Risk, 173 (56.5%) | p-Value |
| Respiratory complications | ||||
| Prolonged mechanical ventilation | 0 (0.0) | 1 (1.0) | 2 (1.2) | >0.999 |
| Atelectasis | 0 (0.0) | 0 (0.0) | 2 (1.2) | - |
| Pneumonia | 0 (0.0) | 0 (0.0) | 4 (2.3) | 0.421 |
| Tracheostomy | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Reintubation | 1 (3.0) | 4 (4.0) | 4 (2.3) | 0.611 |
| Hypoxemia | 4 (12.1) | 14 (14.0) | 26 (15.0) | 0.943 |
| Cardiac complications | ||||
| AF | 5 (15.2) | 12 (12.0) | 12 (6.9) | 0.194 |
| Bradycardia | 0 (0.0) | 3 (3.0) | 5 (2.9) | 0.886 |
| Tachycardia | 2 (6.1) | 5 (5.0) | 3 (1.7) | 0.174 |
| HTN | 2 (6.1) | 21 (21.0) | 61 (35.3) | <0.001* |
| Cardiac arrest | 1 (3.0) | 1 (1.0) | 5 (2.9) | 0.521 |
| MI | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Neurological complications | ||||
| Encephalopathy | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Delirium | 2 (6.1) | 2 (2.0) | 4 (2.3) | 0.355 |
| General complications | ||||
| Weaning time | 878.6±484.9 | 826.1±672.7 | 1061.1±2741.1 | 0.656 |
| Fever | 1 (3.0) | 0 (0.0) | 6 (3.5) | 0.133 |
| Wound infection | 2 (6.1) | 0 (0.0) | 0 (0.0) | 0.011* |
| ICU readmission | 4 (12.1) | 2 (2.0) | 2 (1.2) | 0.006* |
| ICU LoS (day) | 3.0±1.5 | 2.9±1.2 | 2.9±1.3 | 0.975 |
| Postoperation death | 1 (3.0) | 1 (1.0) | 5 (2.9) | 0.521 |
| Insulin infusion in ICU | 12 (36.4) | 44 (44.0) | 94 (54.3) | 0.079 |
Predictors for Respiratory, Cardiac, and Neurological Complications, and ICU LoS
ICU, intensive care unit; LoS, length of stay; OSA, obstructive sleep apnea; HTN, hypertension; DM, diabetes mellitus; LVEF, left ventricular ejection fraction (%); BMI, body mass index (kg/m2); CABG, coronary artery bypass grafting
Values are presented as standardized beta coefficients.
*Statistically significant.
| Postoperative Variables | Respiratory (Model I) | Cardiac (Model II) | Neurological (Model III) | ICU LoS (Model IV) | ||||
| Independent variable | Beta | p-Value | Beta | p-Value | Beta | p-Value | Beta | p-Value |
| OSA | 0.022 | 0.704 | 0.184 | 0.002* | 0.018 | 0.750 | 0.040 | 0.467 |
| Male sex | -0.053 | 0.352 | -0.133 | 0.026* | 0.020 | 0.728 | -0.019 | 0.719 |
| Age | 0.176 | 0.002* | 0.080 | 0.163 | 0.104 | 0.067 | 0.162 | 0.003* |
| HTN | -0.066 | 0.245 | 0.057- | 0.363 | 0.080 | 0.161 | -0.024 | 0.666 |
| DM | -0.161 | 0.005* | 0.001 | 0.984 | -0.016 | 0.781 | 0.007 | 0.896 |
| LVEF<50% | 0.123 | 0.029* | 0.123 | 0.030* | 0.150 | 0.008* | 0.244 | <0.001* |
| BMI ≥ 30 | 0.105 | 0.067 | 0.086 | 0.163 | 0.097 | 0.094 | 0.010 | 0.853 |
| CABG | -0.102 | 0.084 | 0.041- | 0.472 | 0.058 | 0.311 | 0.313- | <0.001* |